We at Bula want to thank pharmacy technicians for their hard work and dedication to public wellness — not just on October 16, but everyday. We appreciate you!
Last year alone, the opioid epidemic accounted for over 8,000 drug overdose deaths in Arizona. To battle this crisis, Arizona policy makers passed more stringent laws addressing opioid medication access. How do these new laws benefit Arizona and impact Arizona pharmacists?
On Tuesday, May 8th, Bula Intelligence CEO, Laura Carpenter, will be presenting at the NCPDP Annual Conference in Scottsdale, Arizona. "NCPDP is a not-for-profit, multi-stakeholder forum for developing and promoting industry standards and business solutions that improve patient safety and health outcomes, while also decreasing costs."
It’s hard to ignore the fact that we are in the midst of a nationwide opioid epidemic. In fact, a nationwide public health emergency was declared on October 26, 2017 as a means to combat the opioid abuse crisis.
Did you attend the American Society for Pharmacy Law Fall Meeting this November in Scottsdale, AZ? If so, you enjoyed some of the most up-to-date, relevant and practical industry information available from the experts. With a goal to provide the pharmacy law industry with learning opportunities, presenters discussed topics such as compounding, ethical policy and big data, auditing, telepharmacy, the DEA and much more.
About DXM abuse behavior and management.
“This is where we really see the industry going. You look at the industry in ten years, the market share for this particular area of the pharmaceutical industry is going to grow significantly.”
By now most people know what a prompt like this is signaling when you see it on your monitor. If you don’t already use it regularly, you at least have heard of it and know that other people are doing this.
Of course, the biochemistry definition paints a bit of a nicer picture describing it as a substance that interferes with or inhibits the physiological action of another. Enter Naloxone, an Opioid Antagonist, and the most famous chemical antagonists of the past few years in Federal and State legislation.